Surgery Partners, Inc. (NASDAQ:SGRY – Get Free Report) insider Marissa Brittenham sold 3,156 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $24.09, for a total value of $76,028.04. Following the sale, the insider now owns 63,408 shares in the company, valued at approximately $1,527,498.72. This represents a 4.74 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Surgery Partners Stock Down 0.0 %
SGRY stock opened at $23.60 on Friday. The company has a current ratio of 1.80, a quick ratio of 1.66 and a debt-to-equity ratio of 0.99. The firm has a market capitalization of $3.01 billion, a PE ratio of -49.17, a PEG ratio of 19.21 and a beta of 2.73. Surgery Partners, Inc. has a 1-year low of $19.50 and a 1-year high of $33.97. The business’s 50 day simple moving average is $23.58 and its 200 day simple moving average is $26.08.
Surgery Partners (NASDAQ:SGRY – Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported $0.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.01. The business had revenue of $864.40 million for the quarter, compared to analyst estimates of $828.09 million. Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. As a group, research analysts anticipate that Surgery Partners, Inc. will post 0.67 EPS for the current year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on SGRY. Macquarie dropped their price objective on Surgery Partners from $34.00 to $33.00 and set an “outperform” rating on the stock in a research note on Tuesday. JPMorgan Chase & Co. dropped their price objective on Surgery Partners from $38.00 to $28.00 and set a “neutral” rating on the stock in a research note on Tuesday, December 3rd. Royal Bank of Canada dropped their price objective on Surgery Partners from $49.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 20th. Finally, Bank of America began coverage on Surgery Partners in a research note on Monday, December 16th. They set a “buy” rating and a $30.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $36.63.
Get Our Latest Stock Report on SGRY
Surgery Partners Company Profile
Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.
Featured Articles
- Five stocks we like better than Surgery Partners
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- What Do S&P 500 Stocks Tell Investors About the Market?
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- The How And Why of Investing in Oil Stocks
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.